Literature DB >> 19695389

Assessing adequate treatment response in patients with rheumatoid arthritis.

Martin Jan Bergman1.   

Abstract

BACKGROUND: Rheumatoid arthritis (RA) presents a substantial socioeconomic burden that is potentially reduced by individualized, appropriate management strategies. Integral to such strategies is recognizing the need for treatment changes when patients inadequately respond or do not respond to treatment. However, there might be little or no agreement as to what constitutes treatment failure or an adequate response. Currently used American College of Rheumatology response criteria and the disease activity score may underestimate the magnitude of treatment failure when applied in clinical practice, and, having been designed to differentiate responses between large groups, they may be of limited value in monitoring individual patients.
OBJECTIVE: The aim of this commentary was to assess how treatment failure and clinical remission/response have been defined in clinical studies.
METHODS: A PubMed search (1948-2009) was conducted to identify clinical studies or reviews containing the following search terms: rheumatoid arthritis and treatment failure, inadequate response, biologic therapy, DMARD, radiographic response, and remission. Select clinical reports in patients with RA were included if remission or treatment failure, radiographic or other, was a study end point.
RESULTS: Thirty-three studies were identified. The present assessment found no consensus as to what represents a practical definition of treatment failure or clinical remission in the clinical studies assessed. The definitions varied from the complete absence of any clinical disease to computer-generated numeric scales. The variability in clinical definitions of treatment failure or remission seems to have been mainly attributed to the time at which assessments were made, making it difficult to determine what treatment failure or remission means in individual patients with RA in clinical practice.
CONCLUSIONS: Based on the findings of the present commentary, standard definitions of treatment failure or clinical remission/response are needed. Aggressive treatment strategies with specific clinical goals may result in better long-term outcomes. Early evidence of treatment effect may serve to improve clinical outcomes, including remission, and help define and align treatment goals in patients with RA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19695389     DOI: 10.1016/j.clinthera.2009.06.005

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  4 in total

1.  Definition of treatment goals for moderate to severe psoriasis: a European consensus.

Authors:  U Mrowietz; K Kragballe; K Reich; P Spuls; C E M Griffiths; A Nast; J Franke; C Antoniou; P Arenberger; F Balieva; M Bylaite; O Correia; E Daudén; P Gisondi; L Iversen; L Kemény; M Lahfa; T Nijsten; T Rantanen; A Reich; T Rosenbach; S Segaert; C Smith; T Talme; B Volc-Platzer; N Yawalkar
Journal:  Arch Dermatol Res       Date:  2010-09-21       Impact factor: 3.017

Review 2.  Applying science in practice: the optimization of biological therapy in rheumatoid arthritis.

Authors:  Sofia Ramiro; Pedro Machado; Jasvinder A Singh; Robert B Landewé; José António P da Silva
Journal:  Arthritis Res Ther       Date:  2010-11-04       Impact factor: 5.156

3.  The number of circulating monocytes as biomarkers of the clinical response to methotrexate in untreated patients with rheumatoid arthritis.

Authors:  Luis Chara; Ana Sánchez-Atrio; Ana Pérez; Eduardo Cuende; Fernando Albarrán; Ana Turrión; Julio Chevarria; Angel Asunsolo del Barco; Miguel A Sánchez; Jorge Monserrat; Alfredo Prieto; Antonio de la Hera; Ignacio Sanz; David Diaz; Melchor Alvarez-Mon
Journal:  J Transl Med       Date:  2015-01-16       Impact factor: 5.531

4.  Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis.

Authors:  Luis Chara; Ana Sánchez-Atrio; Ana Pérez; Eduardo Cuende; Fernando Albarrán; Ana Turrión; Julio Chevarria; Miguel A Sánchez; Jorge Monserrat; Antonio de la Hera; Alfredo Prieto; Ignacio Sanz; David Diaz; Melchor Alvarez-Mon
Journal:  Arthritis Res Ther       Date:  2012-07-27       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.